LARVOL Debuts Cancer Sentiment Analysis Platform

LARVOL, which provides data and intelligence solutions for the pharma and biotech industry, has launched a cancer-focused social media listening and sentiment analysis platform called VIEW.

The company offers competitive intelligence, KOL (key opinion leader) monitoring, and social media listening tools, along with predictive cancer biomarker and clinical trial databases. Its team includes MDs, PhDs and industry professionals around the globe who curate data from more than 25,000 data sources and bring together the most relevant information into reports promising real-time insights and analysis.

LARVOL's new VIEW platform offers trending cancer news curated by experts who focus on the real-time activity of more than 1,500 verified oncologists on Twitter. The firm's analysts manually review and code each tweet to relay a doctor's sentiment towards breaking cancer news - as positive or negative - and resulting data includes influencer ranking and polling data from Twitter's 'top' oncologists.

According to the firm, this analysis enables drug developers and marketers to obtain an accurate read on the competitive landscape, and to identify and engage with DOLs (digital opinion leaders) in oncology. Founder and CEO Bruno Larvol (pictured) comments: 'Top oncologists are now using Twitter to share their opinions on trials, treatments, and the experience of their patients in real time. VIEW gives pharma teams an intuitive platform to tap into the immediate conversations, identify experts, measure sentiment, and more'.

Web site: www.larvol.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.